Alzamend Neuro Inc Financials

ALZN

Source SEC Filings (10-K/10-Q) Updated Oct 31, 2025 Currency USD FYE April

Financial Health Signals

Piotroski F-Score Weak

1/9

Alzamend Neuro Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.45x

For every $1 of reported earnings, Alzamend Neuro Inc generates $1.45 in operating cash flow (-$6.6M OCF vs -$4.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-249.4x

Alzamend Neuro Inc earns $-249.4 in operating income for every $1 of interest expense (-$4.5M vs $18K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Alzamend Neuro Inc (ALZN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$4.4M

YoY+55.0%

Alzamend Neuro Inc's EBITDA was -$4.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.0% from the prior year.

Free Cash Flow

N/A

Net Income

-$4.5M

YoY+54.6%

Alzamend Neuro Inc reported -$4.5M in net income in fiscal year 2025. This represents an increase of 54.6% from the prior year.

EPS (Diluted)

$-11.32

Alzamend Neuro Inc earned $-11.32 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.4% from the prior year.

Cash & Debt

$5.6M

YoY+370.8%

5Y CAGR+145.4%

Alzamend Neuro Inc held $5.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Alzamend Neuro Inc had 3M shares outstanding in fiscal year 2025. This represents an increase of 244.3% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$1.4M

YoY-78.1%

5Y CAGR+5.8%

Alzamend Neuro Inc invested $1.4M in research and development in fiscal year 2025. This represents a decrease of 78.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ALZN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.4M-78.1%	$6.5M-13.3%	$7.4M+43.2%	$5.2M+296.8%	$1.3M+22.6%	$1.1M
SG&A Expenses	$3.1M-11.5%	$3.5M-53.1%	$7.4M+4.3%	$7.1M+95.5%	$3.6M+8.5%	$3.4M
Operating Income	-$4.5M+54.7%	-$9.9M+33.2%	-$14.9M-20.7%	-$12.3M-148.8%	-$5.0M-11.9%	-$4.4M
Interest Expense	$18K+78.5%	$10K+31.2%	$8K-83.4%	$47K-67.3%	$142K+922.8%	$14K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.5M+54.6%	-$9.9M+33.1%	-$14.9M-20.4%	-$12.4M-145.0%	-$5.0M-14.4%	-$4.4M
EPS (Diluted)	$-11.32	$-132.33	$-22.89-16250.0%	$-0.14	N/A	N/A

Metric	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23	Q1'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$176K-89.9%	$1.7M+289.4%	$447K+43.7%	$311K+50.6%	$207K-89.2%	$1.9M-4.4%	$2.0M-15.6%	$2.4M
SG&A Expenses	$822K-14.3%	$959K+62.5%	$590K-43.6%	$1.0M+38.5%	$756K+0.6%	$751K-17.0%	$905K-22.0%	$1.2M
Operating Income	-$998K+63.0%	-$2.7M-160.3%	-$1.0M+23.6%	-$1.4M-41.1%	-$962K+63.8%	-$2.7M+8.3%	-$2.9M+17.7%	-$3.5M
Interest Expense	$3K+6.7%	$2K+23.0%	$2K-42.2%	$3K-70.9%	$12K+382.6%	$2K-42.3%	$4K+134.9%	$2K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.0M+63.0%	-$2.7M-160.0%	-$1.0M+23.7%	-$1.4M-39.7%	-$974K+63.4%	-$2.7M+8.4%	-$2.9M+17.6%	-$3.5M
EPS (Diluted)	$-0.30+76.6%	$-1.28-573.7%	$-0.19+94.7%	$-3.61	$-11.42	$-3.77	$-4.43+17.7%	$-5.38

ALZN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$6.3M+278.9%	$1.7M-36.5%	$2.6M-78.5%	$12.2M-27.4%	$16.8M+827.1%	$1.8M
Current Assets	$5.9M+318.6%	$1.4M-41.3%	$2.4M-80.1%	$12.1M-28.0%	$16.8M+827.1%	$1.8M
Cash & Equivalents	$5.6M+370.8%	$1.2M-29.6%	$1.7M-85.3%	$11.5M-26.2%	$15.6M+24646.0%	$63K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$983K-65.9%	$2.9M+5.2%	$2.7M+166.4%	$1.0M-30.2%	$1.5M-17.6%	$1.8M
Current Liabilities	N/A	N/A	N/A	$1.0M-30.2%	$1.5M+48.5%	$992K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.3M+540.8%	-$1.2M-974.0%	-$113K-101.0%	$11.2M-27.1%	$15.3M+59217.5%	$26K
Retained Earnings	-$61.2M-11.4%	-$55.0M-15.5%	-$47.6M-47.7%	-$32.2M-68.3%	-$19.2M-62.5%	-$11.8M

Metric	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23	Q1'23
Total Assets	$5.1M-19.5%	$6.3M+51.5%	$4.2M-16.6%	$5.0M+199.9%	$1.7M+113.4%	$783K-20.4%	$984K-62.6%	$2.6M
Current Assets	$4.7M-20.4%	$5.9M+50.2%	$3.9M-17.2%	$4.8M+236.6%	$1.4M+138.6%	$594K-24.1%	$782K-67.6%	$2.4M
Cash & Equivalents	$4.4M-20.8%	$5.6M+67.4%	$3.4M-18.0%	$4.1M+242.8%	$1.2M+322.1%	$283K+41.4%	$200K-88.2%	$1.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$717K-27.0%	$983K+35.5%	$726K-42.2%	$1.3M-56.5%	$2.9M-42.9%	$5.0M+37.7%	$3.7M+33.8%	$2.7M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	$3.8M	N/A	$2.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.4M-18.1%	$5.3M+54.9%	$3.4M-8.1%	$3.8M+409.6%	-$1.2M+71.6%	-$4.3M-58.9%	-$2.7M-2276.3%	-$113K
Retained Earnings	-$62.2M-1.6%	-$61.2M-6.7%	-$57.4M-1.7%	-$56.4M-2.6%	-$55.0M-3.4%	-$53.2M-5.3%	-$50.5M-6.1%	-$47.6M

ALZN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.6M+20.6%	-$8.3M+7.3%	-$8.9M-34.9%	-$6.6M-143.9%	-$2.7M-15.6%	-$2.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$300K-103.7%	-$147K	N/A	-$106K-205.5%	$101K-3.9%	$105K
Financing Cash Flow	$10.4M+185.9%	$3.7M+1826112.5%	$200-100.0%	$18.9M+323.7%	$4.5M+94.5%	$2.3M
Dividends Paid	$117K	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23	Q1'23
Operating Cash Flow	-$1.2M+50.4%	-$2.4M-66.0%	-$1.4M+58.1%	-$3.4M-222.1%	-$1.1M+48.0%	-$2.0M-34.2%	-$1.5M+54.1%	-$3.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$210K	N/A	$0	$0+100.0%	-$90K	$0	$0+100.0%	-$147K
Financing Cash Flow	$0-100.0%	$4.0M+485.9%	$689K-89.1%	$6.3M+220.8%	$2.0M-7.1%	$2.1M	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ALZN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-71.4%+524.4pp	-595.7%-29.6pp	-566.1%-464.9pp	-101.2%-71.2pp	-30.0%+213.1pp	-243.1%
Current Ratio	N/A	N/A	N/A	11.78+0.4	11.41+9.6	1.83
Debt-to-Equity	0.18+2.6	-2.38+21.9	-24.28-24.4	0.090.0	0.10-69.0	69.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23	Q1'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-19.7%+23.1pp	-42.7%-17.8pp	-24.9%+2.3pp	-27.2%+31.2pp	-58.4%+281.8pp	-340.2%-44.7pp	-295.4%-161.2pp	-134.2%
Current Ratio	N/A	N/A	N/A	N/A	N/A	0.16	N/A	2.03
Debt-to-Equity	0.16-0.0	0.18-0.0	0.21-0.1	0.33+2.7	-2.38-1.2	-1.18+0.2	-1.37+22.9	-24.28
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Adial Pharmaceuticals Inc ADIL

$3.2M

Brainstorm Cell Therapeutics I BCLI

$12.0M

TNF Pharmaceuticals TNFA

$9.6M

Vyne Therapeutics Inc VYNE

$19.0M

Impact Biomedical, Inc. IBO

$46.6M

Frequently Asked Questions

Is Alzamend Neuro Inc profitable?

No, Alzamend Neuro Inc (ALZN) reported a net income of -$4.5M in fiscal year 2025.

What is Alzamend Neuro Inc's earnings per share (EPS)?

Alzamend Neuro Inc (ALZN) reported diluted earnings per share of $-11.32 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Alzamend Neuro Inc's EBITDA?

Alzamend Neuro Inc (ALZN) had EBITDA of -$4.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Alzamend Neuro Inc's operating cash flow?

Alzamend Neuro Inc (ALZN) generated -$6.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Alzamend Neuro Inc's total assets?

Alzamend Neuro Inc (ALZN) had $6.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Alzamend Neuro Inc spend on research and development?

Alzamend Neuro Inc (ALZN) invested $1.4M in research and development during fiscal year 2025.

How many shares does Alzamend Neuro Inc have outstanding?

Alzamend Neuro Inc (ALZN) had 3M shares outstanding as of fiscal year 2025.

What is Alzamend Neuro Inc's debt-to-equity ratio?

Alzamend Neuro Inc (ALZN) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Alzamend Neuro Inc's return on assets (ROA)?

Alzamend Neuro Inc (ALZN) had a return on assets of -71.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Alzamend Neuro Inc's cash runway?

Based on fiscal year 2025 data, Alzamend Neuro Inc (ALZN) had $5.6M in cash against an annual operating cash burn of $6.6M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Alzamend Neuro Inc's Piotroski F-Score?

Alzamend Neuro Inc (ALZN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Alzamend Neuro Inc's earnings high quality?

Alzamend Neuro Inc (ALZN) has an earnings quality ratio of 1.45x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Alzamend Neuro Inc cover its interest payments?

Alzamend Neuro Inc (ALZN) has an interest coverage ratio of -249.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.